Predictors of Severe Morbidity After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis

被引:0
作者
Geert A. Simkens
Thijs R. van Oudheusden
Misha D. Luyer
Simon W. Nienhuijs
Grard A. Nieuwenhuijzen
Harm J. Rutten
Ignace H. de Hingh
机构
[1] Catharina Hospital,Department of Surgical Oncology
来源
Annals of Surgical Oncology | 2016年 / 23卷
关键词
Peritoneal Carcinomatosis; Severe Morbidity; Brier Score; Hyperthermic Intraperitoneal Chemotherapy; Colorectal Origin;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:833 / 841
页数:8
相关论文
共 104 条
[1]  
Elias D(2010)Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study J Clin Oncol. 28 63-68
[2]  
Gilly F(2009)Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality Ann Surg. 249 900-907
[3]  
Boutitie F(2014)Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients Dis Colon Rectum. 57 858-868
[4]  
Chua TC(2015)Serious postoperative complications affect early recurrence after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis Ann Surg Oncol. 22 2656-2662
[5]  
Yan TD(2014)Quality of life after cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: a systematic review Eur J Surg Oncol. 40 1605-1613
[6]  
Saxena A(2014)The burden of gastrointestinal anastomotic leaks: an evaluation of clinical and economic outcomes J Gastrointest Surg. 18 1176-1185
[7]  
Morris DL(2012)Identification of a subgroup of patients at highest risk for complications after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy Ann Surg. 256 334-341
[8]  
Baratti D(2013)Predicting postoperative morbidity following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS + HIPEC) with preoperative FACT-C (Functional Assessment of Cancer Therapy) and patient-rated performance status Ann Surg Oncol. 20 3519-3526
[9]  
Kusamura S(2015)Significance of diabetes on morbidity and mortality following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy J Surg Oncol. 111 740-745
[10]  
Iusco D(2012)Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy J Clin Oncol. 30 2449-2456